Literature DB >> 15561480

The acute and sub-acute effects of 'ecstasy' (MDMA) on processing of facial expressions: preliminary findings.

Rosa Hoshi1, Jatinder Bisla, H Valerie Curran.   

Abstract

RATIONALE: There is evidence that serotonergic processes may modulate the processing of fearful facial expressions. It is therefore possible that the recreational drug 'ecstasy' (MDMA), which has marked serotonergic effects, may affect people's ability to recognise human facial expressions portraying fear.
OBJECTIVE: The present study therefore aimed to determine whether ecstasy users differed from controls in fear recognition at two time points: shortly after taking the drug and a few days later.
METHODS: Sixteen ecstasy users and 21 controls were compared on a facial expression recognition task involving the 6 basic emotions (happiness, surprise, sadness, anger, fear and disgust) and on self-ratings of mood on the night of drug use (day 0) and 4 days later (day 4).
RESULTS: In recognising fearful facial expressions, ecstasy users were more accurate than controls on day 0 but less accurate than them on day 4 when compared with their overall ability to recognise other basic emotions. Accuracy of fear recognition on day 4 was negatively correlated with both years of ecstasy use and number of ecstasy tablets taken on a typical session. On self-rated aggression scales, ecstasy users scored lower than controls on day 0 and higher on day 4.
CONCLUSIONS: These results support the notion that 5-HT plays a role in modulating the recognition of fearful facial expressions. Increased accuracy of fear recognition may relate to 5-HT release following ecstasy use on day 0, and decreased accuracy may reflect subsequent depletion of 5-HT mid-week.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15561480     DOI: 10.1016/j.drugalcdep.2004.06.006

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  9 in total

Review 1.  The role of cognitive control in cocaine dependence.

Authors:  Hugh Garavan; Robert Hester
Journal:  Neuropsychol Rev       Date:  2007-08-07       Impact factor: 7.444

2.  Emotion, decision-making and substance dependence: a somatic-marker model of addiction.

Authors:  A Verdejo-García; M Pérez-García; A Bechara
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

Review 3.  A somatic marker theory of addiction.

Authors:  Antonio Verdejo-García; Antoine Bechara
Journal:  Neuropharmacology       Date:  2008-08-05       Impact factor: 5.250

4.  The neuropsychology of cocaine addiction: recent cocaine use masks impairment.

Authors:  Patricia A Woicik; Scott J Moeller; Nelly Alia-Klein; Thomas Maloney; Tanya M Lukasik; Olga Yeliosof; Gene-Jack Wang; Nora D Volkow; Rita Z Goldstein
Journal:  Neuropsychopharmacology       Date:  2008-05-21       Impact factor: 7.853

5.  Alexithymia and Addiction: A Review and Preliminary Data Suggesting Neurobiological Links to Reward/Loss Processing.

Authors:  Kristen P Morie; Sarah W Yip; Charla Nich; Karen Hunkele; Kathleen M Carroll; Marc N Potenza
Journal:  Curr Addict Rep       Date:  2016-04-11

6.  Relationships Between Alexithymia and Psychopathy in Heroin Dependent Individuals.

Authors:  Elena Psederska; Svetoslav Savov; Nikola Atanassov; Jasmin Vassileva
Journal:  Front Psychol       Date:  2019-10-09

7.  Impaired fear recognition in regular recreational cocaine users.

Authors:  L Kemmis; J K Hall; R Kingston; M J Morgan
Journal:  Psychopharmacology (Berl)       Date:  2007-06-08       Impact factor: 4.415

8.  Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions.

Authors:  Débora González; Marta Torrens; Magí Farré
Journal:  Biomed Res Int       Date:  2015-10-12       Impact factor: 3.411

9.  Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment.

Authors:  Anna Borissova; Bart Ferguson; Matthew B Wall; Celia Ja Morgan; Robin L Carhart-Harris; Mark Bolstridge; Michael Ap Bloomfield; Tim M Williams; Amanda Feilding; Kevin Murphy; Robin J Tyacke; David Erritzoe; Lorna Stewart; Kim Wolff; David Nutt; H Valerie Curran; Will Lawn
Journal:  J Psychopharmacol       Date:  2020-06-15       Impact factor: 4.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.